Clearside starts Phase II trial of CLS-TA to treat macular edema associated with RVO
US-based biopharmaceutical firm Clearside Biomedical has started patient enrolment in a Phase II trial of its proprietary formulation of triamcinolone acetonide, CLS-TA, to treat macular edema associated with retinal vein occlusion (RVO).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Triamcinolone